These early studies documented a three‐ to five‐fold increase in precursor differentiation into DAergic neurons, paving the way for the use of GSK‐3β inhibitors to improve stem/precursor cell therapy approaches in Parkinson's disease (Arenas, 2014; Brodski et al., 2019; Esfandiari et al., 2012; Kirkeby et al., 2012; Kirkeby, Parmar, & Barker, 2017; Kriks et al., 2011; Parish et al., 2008; Parish & Thompson, 2014; Toledo et al., 2017). The gene discussed is GSK3B; the disease is Parkinson disease.